UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

A PROSPECTIVE, RANDOMIZED TRIAL COMPARING PROPOFOL AND REMIMAZOLAM FOR SEDATION IN ADVANCED ENDOSCOPIC PROCEDURES

Alina Liliana Constantin 1, Nicoleta Podina 1, Despina Ungureanu 1, Ruxandra Pop 1, Iulia-Cristina Stoicoiu 2, Mihaela Roxana Badescu 1, Adrian Săftoiu 3

Affiliations

1 Ponderas Academic Hospital, Bucharest, Romania

2 Fundeni Clinical Institute, Bucharest, Romania

3 Elias Emergency University Hospital, Bucharest, Romania

Summary

AI Generated

A randomized single-blind trial of 100 patients found remimazolam comparable to propofol for sedation in advanced endoscopy with significantly fewer hypotensive episodes and respiratory interventions.

Both remimazolam and propofol provided adequate sedation with no significant difference in procedural success rates in 50 patients per group undergoing ERCP, EUS, or EMR.
Remimazolam was associated with significantly fewer hypotensive episodes and respiratory interventions compared to propofol (p < 0.05 for both).
Recovery time was comparable between groups, while patient satisfaction was higher with remimazolam and endoscopists reported similar ease of procedure in both arms.
The authors conclude remimazolam appears to be a safe and effective alternative to propofol with potential role in settings with limited anesthesiology support or higher-risk patients.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Effective sedation is essential for patient safety and procedural success during advanced endoscopic interventions. Propofol, although effective, has a narrow therapeutic index and can lead to significant cardiopulmonary depression. Remimazolam, a novel ultra-short-acting benzodiazepine, may offer comparable efficacy with improved safety and recovery profiles. This study aimed to compare the efficacy, safety, and recovery characteristics of remimazolam versus propofol in advanced endoscopy.

Aims & Methods

This was a prospective, randomized, single-blind trial including adult patients undergoing advanced endoscopic procedures (e.g., ERCP, EUS, EMR). Participants were randomized to receive sedation with either propofol or remimazolam. Sedation depth was monitored using the Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) scale. Primary outcome was adequate sedation without rescue medication. Secondary outcomes included cardiopulmonary adverse events, recovery time, and patient and endoscopist satisfaction.

Results

A total of 100 patients were enrolled, with 50 in the propofol group and 50 in the remimazolam group.Both agents provided adequate sedation, with no significant difference in procedural success rates. Remimazolam was associated with significantly fewer hypotensive episodes (p < 0.05) and respiratory interventions (p < 0.05). Recovery time maintained comparable between groups, though patient satisfaction remained higher in remimazolam group. Endoscopists reported a similar ease of procedure in both arms.

Conclusion

Remimazolam appears to be a safe and effective alternative to propofol for sedation in advanced endoscopy, with a favorable safety profile regarding cardiovascular and respiratory events. These findings support its potential role in settings where anesthesiology support is limited or in patients at increased sedation risk.

References

Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the safety and efficacy of remimazolam compared with placebo and midazolam for sedation in colonoscopy. Gastrointest Endosc. 2018;88(3):427–437.e6.
Chen S, Wang J, Xu X, et al. Efficacy and safety of remimazolam for procedural sedation: a meta-analysis of randomized controlled trials. J Clin Anesth. 2022;76:110584
Safety and efficacy of remimazolam versus propofol during EUS: a multicenter randomized controlled studyChoe, Jung Wan et al.
Gastrointestinal Endoscopy, Volume 100, Issue 2, 183 - 191.e1
Remimazolam versus propofol for sedation in gastrointestinal endoscopic procedures: a systematic review and meta-analysisBarbosa, Eduardo Cerchi et al. British Journal of Anaesthesia, Volume 132, Issue 6, 1219 - 1229

Disclosure

I do not have any conflict of interest

Conference

UEG Week Berlin 2025

Topics

Colorectal

Submission format

Abstract

Session

Important issues in colonoscopy (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Developing a nurse-led counselling service in hepatology across two hospitals

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman 1

Affiliations

1 None, None, Switzerland

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Nurses

Session

Innovative approaches in liver disease management

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Troubleshooting: What to do if your scope looks unusual after processing?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath 1

Affiliations

1 None, Hamburg, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Nurses

Session

New trends and developments in hygiene and infection control

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Round table: What is the future of endoscopy nursing?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Round table: What is the future of endoscopy nursing?

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Nurses

Session

ESGENA: Opening Session

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli 1

Affiliations

1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Nurses

Session

Patient care: Differences matter

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

See It. Learn It. Use It: The new EUS-FNB needle in action

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti 1

Affiliations

1 Hospital of Imola, University of Bologna, Bologna, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Nurses

Session

New trends and developments in endoscopic techniques

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Daniel Habich 1, Angela Horvath 2, Nicole Feldbacher 2, Lavra Celcer 2, Vanessa Stadlbauer-Köllner 2

Affiliations

1 Center for Biomarker Research in Medicine (CBmed), Graz, Austria

2 Center for Biomarker Research in Medicine (CBmed), Graz, Austria|||Medical University of Graz, Graz, Austria

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Liver cirrhosis is characterized by microbial dysbiosis, intestinal inflammation and a weakened gut barrier and associated with an increased risk of complications. We previously observed a positive influence of L-ornithine-L-aspartate (LOLA) on gut microbiome composition in cirrhosis (1). The current study aimed to investigate the effect of LOLA on microbiome dysbiosis, quality of life, sarcopenia, intestinal permeability, inflammation and metabolite composition.

Aims & Methods

In this monocentric, open-label, phase 4 study, LOLA (18g/day) was administered orally for three months to liver cirrhosis patients with hepatic encephalopathy grades (0-2). We investigated changes in their gut microbiome composition (16s rRNA sequencing, alpha and beta diversity, differential abundance), quality of life (SF36), blood ammonia concentrations, measurements of sarcopenia and frailty (appendicular lean muscle mass, anthropometric measures, liver frailty index, SARC-F), biomarkers of gut permeability, inflammation and sarcopenia as well as metabolic alterations in stool, serum, and urine.

Results

65 patients were enrolled, and 52 patients completed the 3-month study (40.4% female, age 62 (58; 65)). While LOLA reduced the abundance of the genus Romboutsia, it did not significantly change overall microbiome diversity. LOLA led to a significant improvement in the vitality dimension of the SF36 questionnaire (45 (35; 60) to 50 (45; 60), p=0.019) and decreased plasma ammonia levels in patients with elevated baseline ammonia (69.5 (54; 225) to 46.0 (22; 66) µmol/L, p=0.004) Although muscle mass generally declined across the study, this was not observed in patients whose elevated ammonia levels improved. Sarcopenia and frailty scores and the muscle biomarkers myostatin, irisin, fibroblast growth factor 21, insulin-like growth factor 1 were unaffected by LOLA treatment. Diamine oxidase, a marker of gut barrier dysfunction, significantly decreased (from 12.75 U/mL (11.25; 17.45) to 11.15 U/mL (9.9; 15.65), p=0.016), while LPS binding protein, a marker of innate immune response to bacterial translocation, significantly increased (from 17.05 µg/mg (14.7; 19.8) to 17.39 µg/mg (16.2; 21.9), p=0.006). Calprotectin, zonulin and sCD14 did not show significant changes. Metabolomic analysis revealed an increase in serum alanine levels (pFDR=0.014) with additional subtle shifts in lipoprotein and amino acid profiles.

Conclusion

In summary, LOLA was associated with an improvement in vitality, an important patient-reported outcome accompanied by alterations in gut microbial composition and prevented muscle loss in patients with hyperammonaemia. Furthermore, LOLA was associated with improvements in gut permeability and endotoxin handling. The slight increase in alanine observed in the metabolomics analysis may be a consequence of LOLA metabolism. LOLA may be a valuable supportive treatment for enhancing quality of life in cirrhosis by targeting the gut liver axis and may be particularly beneficial in preventing muscle loss in patients with hyperammonaemia.

References

1. Horvath A, Traub J, Aliwa B, Bourgeois B, Madl T, Stadlbauer V. Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis. Nutrients. 2022 Feb 10;14(4):748.

Conference

UEG Week Berlin 2025

Topics

Hepatobiliary

Submission format

Abstract

Session

LIVER (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Developing a nurse-led counselling service in hepatology across two hospitals

Sonja Beckman

Troubleshooting: What to do if your scope looks unusual after processing?

Ilona Reifenrath

Round table: What is the future of endoscopy nursing?

Perceived satisfaction of outpatients undergoing endoscopic examination: Cross-sectional observational study

Fabio Grilli

See It. Learn It. Use It: The new EUS-FNB needle in action

Andrea Lisotti

EFFECTS OF LOLA ON THE GUT MICROBIOME AND PATIENT REPORTED QUALITY OF LIFE

Vanessa Stadlbauer-Köllner

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!